Nafarelin
Top View
- Elagolix (Orilissa™, Oriahnn™) EOCCO POLICY
- Effects of a New Steroidal Aromatase Inhibitor, TZA-2237, And/Or Chlormadinone Acetate on Hormone-Induced and Spontaneous Canine Benign Prostatic Hyperplasia
- Nafarelin Acetate (Synarel) Reference Number: PA.CP.PHAR.174 Effective Date: 01/18 Coding Implications Last Review Date: 02/17 Revision Log
- Effect of Chronic Treatment with the Gonadotrophin-Releasing Hormone Agonist Azagly-Nafarelin on Basal Concentrations of LH in Prepubertal Bulls
- SYNAREL (Nafarelin)
- Gonadotropin Releasing Hormone Analogs (Gnrh)
- Gonadorelin Analogues for Endometriosis
- Therapeutic Class Overview Gonadotropin-Releasing Hormone (Gnrh) Agonists/ Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- Nafarelin Acetate (Synarel®) Is a Gonadotropin-Releasing Hormone (Gnrh) Receptor Agonist
- A Women's Health Update
- Synarel® (Nafarelin Acetate) Nasal Solution
- Clinical Criteria
- Response to ICER's Draft Scoping Document Regarding Elagolix for Endometriosis Abbvie Appreciates the Opportunity to Provide C
- Hirsutism Acne and Hair Loss Management Of
- Does the Addition of Gonadotropin-Releasing Hormone Analogs Improve the Pregnancy Rates in Intrauterine Insemination?
- (12) United States Patent (10) Patent No.: US 6,265,393 B1 Heinrichs (45) Date of Patent: *Jul
- Study Protocol and Statistical Analysis Plan
- Comparative Response of Rams and Bulls to Long-Term Treatment with Gonadotropin-Releasing Hormone Analogs